Objective: Ketogenic diets reduce seizures in children with drug-resistant epilepsy. Whether adults benefit from similar treatment has not been clarified. We therefore examined the efficacy of the modified Atkins diet in adults with drug-resistant focal epilepsy.

Methods: We performed a randomized clinical trial (RCT) with patients >16 years who had at least 3 seizures per month despite having tried at least 3 antiepileptic drugs. They were randomized to either 12 weeks on the modified Atkins diet (diet group) or habitual diet (control group). Primary endpoint was a change in seizure frequency from baseline to the intervention period, comparing those on diet with controls.

Results: We assigned 37 patients to the diet group and 38 to the control group. Nine of the patients in the diet group and 4 controls were excluded. Of those who completed the dietary intervention (n = 24), median seizure change was -1.0 (interquartile range [IQR] -13.7-8.8), while in the control group (n = 32) the median change was 4.5 (IQR -4.8-33.5). The median difference between the groups was -7.0 (95% confidence interval [CI] -37.0-3.0; P = .21). In the intention-to-treat analysis, the relative risk (RR) for achieving >50% seizure reduction was 1.8 (95% CI 0.3-10.2; P = .65), while for achieving >25% seizure reduction RR was 2.43 (95% CI 0.94-6.28; P = .06). We observed no serious adverse events.

Significance: In this RCT investigating the effect of an adjunctive modified Atkins diet on seizure frequency in adults with difficult-to-treat focal epilepsy, we found a significant reduction in seizure frequency in the diet group compared to the controls, but only for moderate benefit (>25% seizure reduction) among those who completed the intervention. However, seizure response varied considerably between individuals, perhaps negatively influenced by a drop in serum concentrations of antiepileptic drugs.

Download full-text PDF

Source
http://dx.doi.org/10.1111/epi.14457DOI Listing

Publication Analysis

Top Keywords

modified atkins
16
atkins diet
16
diet group
16
control group
12
seizure frequency
12
seizure reduction
12
diet
10
diet adults
8
adults drug-resistant
8
drug-resistant focal
8

Similar Publications

Importance: Women who use heroin in sub-Saharan Africa face elevated HIV risk linked to structural vulnerability including frequent incarceration. However, little is known about the association between incarceration and drug use and HIV outcomes among women who use heroin in Africa.

Objective: To estimate associations between incarceration and adverse HIV-related and drug use-related outcomes among women who used heroin.

View Article and Find Full Text PDF

Despite advances in pharmacological therapies, migraine patients are often drug resistant. Further therapeutic options in this field are, therefore, desirable. Recent studies have highlighted the efficacy of ketogenic diet (KD) on improving migraine, but data on their long-term efficacy and safety are lacking.

View Article and Find Full Text PDF

[Micronutrients intake in patients with refractory epilepsy with ketogenic diet treatment].

Andes Pediatr

October 2024

Facultad de Medicina, Departamento de Gastroenterología y Nutrición Pediátrica, Pontificia Universidad Católica de Chile, Santiago, Chile.

Unlabelled: The Ketogenic Diet (KD) is a non-pharmacological strategy for drug-resistant epilepsy (DRE) and inborn errors of metabolism (Glut-1 deficiency) management. KD is characterized by being restrictive, affecting micronutrient intake. There are different modalities of KD in which food intake and nutritional deficiencies vary.

View Article and Find Full Text PDF
Article Synopsis
  • CheckMate 204 study found that the combination of nivolumab and ipilimumab resulted in high intracranial objective response rates (icORRs) for patients with melanoma brain metastases (MBMs), prompting a need for standardized response criteria.
  • Different assessment criteria (like mRECIST and volumetric measurements) showed higher icORRs and stronger correlations with progression-free survival (icPFS) and overall survival (OS) compared to RANO-BM and RECIST.
  • The analysis suggests that mRECIST and volumetric criteria are reliable scales for future MBM trials, and response can be effectively measured even in patients with small lesions (<10 mm).
View Article and Find Full Text PDF

Osimertinib is first-line treatment for epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC) and has been associated with cardiotoxicity. However, the nature of cardiac remodeling and associated risk factors remains incompletely understood. Retrospective analysis of NSCLC patients with ≥1 echocardiogram post-osimertinib between 2007 and 2022 was performed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!